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ABSTRACT
Developing a cellular assay for screening inhibitors of STAT4 phosphorylation
Vivian Marcela Suarez

In order to design better therapeutic strategies, scientists work on understanding
the interactions that take place at cell level and have an effect on the immune
system. In order to identify a few possible inhibitors that may be up-regulated in
tumor environment and that may affect T-cell action, a cellular assay was
designed. An Interleukin-12 (IL-12)-responsive murine Th1 cell clone called 2D6
was used as cellular model to study the effects of transforming growth factor-β
(TGF-β), insulin, and interleukin-6 (IL-6) on the phosphorylation of Signal
transducer and activator of transcription 4 (STAT4), a key element in IL-12
signaling. Cells were IL-12-starved for 12 hours and then were treated for 15
minutes, 1 hour and 2 hours with one of these factors and/or IL-12 and the cell
samples were analyzed by flow cytometry. In general, TGF-β and insulin had a
significant effect in the phosphorylation of STAT4 and cell viability particularly
after 2 hours in cells incubated with these factors only. While more subtle, the
effects of IL-6 also seemed to be have a stronger effect after 2 hours of
treatment. The assay designed was able to provide with answers about inhibition
of IL-12 signaling in a relatively restricted time frame, but more questions need to
be answered to fully understand the effect of each factor, for which a new
experimental approach may be needed.
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CHAPTER ONE:
INTRODUCTION
As more knowledge is gained on the ins and outs of the immune system it
becomes more clear that the mechanisms for the defense against disease and
pathogens engages a plethora of intermolecular interactions that lead to a final effect
in the organism. Based on these interactions, scientists work on developing
therapeutic strategies for the treatment of diseases that either trigger or block certain
interactions at cell level. The design of such molecular triggers/stops (i.e. drugs)
requires a good understanding of the effects of changes in interactions such as
protein signaling in order to be able to manipulate them. It is also important to
visualize the signaling events as part of a whole, and to understand that the
components may receive signals from more than one source at a time, leading to an
action that may result from this crosstalk of signals. In order to study this complex of
signals and responses, a model cell line from the immune system was used to
develop a cellular assay that would mimic the presence of different factors in the
tumor microenvironment where there can be overexpression of many molecules, and
to quantify the inhibiting effect that such factors could have on the cell’s mechanism
of action.
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CHAPTER TWO:
LITERATURE REVIEW

1.1 Innate immune system
One of nature’s most amazing systems is the complex network that
encompasses all the structures and processes that take place in an organism to
protect and defend it from external agents that may pose a threat. The first line of
defense after the protective barriers (skin, mucus, proteases and gastric acid in
stomach, etc) have been crossed by pathogens is the innate system that is said to be
non-specific although triggered when the pattern-recognition receptors (PRRs)
identify microbes. These PRRs have evolved so that they detect components in
foreign pathogens, called pathogen-associated molecular patterns (PAMPs) (Kawai,
Akira 2010). The innate response is also triggered by damaged or stressed cells that
send a signal of alarm leading to the recruitment of inflammatory cells.

An important component of the innate response is the presence of leukocytes
such as neutrophils and macrophages, which are phagocytes that attack pathogens
and kill them by engulfing them or by mere contact. The most common type of
leukocyte is the neutrophil, and the cells of this type engulf damaged tissue and
bacteria and secrete proteolytic enzymes to kill microbes (VanderLaan, Reardon
2005).
Other important members of the innate response are the mast cells, which are
cells that are involved in inflammation and hypersensitivity (allergy) reactions. They
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are mainly activated when degranulated upon cross-linking of the immunoglobulin E
(IgE) to the antigen receptor (i.e. FcεR1) followed by antigen binding. After this, they
release the contents of their granules, which are vasoactive substances (i.e. have an
effect on blood pressure) such as histamines, proteolytic enzymes like tryptase, and
inflammatory cytokines like tumor necrosis factor-α (TNF- α). They also secrete other
cytokines (proteins that carry a signal between cells) that can regulate T-cell and
macrophage responses, such as interleukins 6 and 10 (VanderLaan, Reardon 2005)
(Galli, Gordon & Wershil 1991).
Some lymphocytes like the natural killer cells (NK) play an exceptionally
important role in innate immunity against diseases such as cancer, due to their
intrinsic ability to lyse tumor cells, hence their name (VanderLaan, Reardon
2005)(Herberman, Nunn & Lavrin 1975). These cells are important since they provide
an early response while the adaptive system mounts an effective response
(Yokoyama, Kim & French 2004). They perform cell-mediated cytotoxicity by
releasing granules that contain perforin and granzymes; these proteins drill holes in
cell membranes and lend to the lysis of target cells. NK cells also release cytokines
that activate other effector cells such as T-lymphocytes (VanderLaan, Reardon 2005).

1.2The bridge between innate and adaptive immunity
The inflammatory cascade involves several important steps such as the
presentation of the antigen to T-lymphocytes. Dendritic cells (DCs) are efficient
antigen-presenting cells that can regulate immune responses to foreign and selfantigens and have a unique T-cell stimulatory capacity (Heath, Carbone 2009). The
3

immature dendritic cell samples the antigen by internalizing (receptor-mediated
endocytosis) its particles in the form of vesicles that are subsequently fused with
lysosomes and broken down. DCs also express Toll-like receptors that, upon
stimulation, induce dendritic cell maturation. When mature, the cell undergoes a
decrease in endocytic activity and an increase in the expression of antigenpresentation molecules (i.e. MHC I and II, CD1), costimulatory molecules and the
secretion of inflammatory cytokines like Interleukin 12 (IL-12) and tumor-necrosis
factor- α (TNF-α) (VanderLaan, Reardon 2005)(Iwasaki, Medzhitov 2004)(Bobryshev
2000).
An interesting group of the cells that are members of the adaptive immune
response and have receptors specific to some antigens are γδ T-lymphocytes (see
Adaptive immune system). They are a small population of T-cells that have limited
diversity in their receptors, but are thought to be important in the defense against
certain pathogens and can either activate or suppress other subsets of lymphocytes
(VanderLaan, Reardon 2005). They produce cytokines that are also produced by the
other subsets of T-lymphocytes such as interleukin 10 (IL-10) and interferon-γ (IFNγ), and unlike traditional αβ T-cells they do not need antigen presentation in the
context of major histocompatibility complex (MHC) molecules to respond to the
antigen, which is why they are considered bridging cells in the immune system
(Aljurf, Ezzat & Mussa M. 2002).
Another intriguing subset of lymphocytes is that of the NKT cells, characterized
by expressing the NK cell markers and the T-cell receptors, thus sharing
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characteristics from both innate immunity and adaptive immunity cell-type members.
These cells bridge the gap between the early and late immunity by inducing NK cells
to produce cytokines upon NKT activation, and by promoting B-lymphocyte
proliferation and antibody production (Galli et al. 2003).

1.3 Adaptive immune system
The immune system has a highly sophisticated feature that confers organisms
with protection against infection from most pathogens. The adaptive immune system
is characterized by a genetically diverse repertoire that allows anticipation to
pathogen infection by arming each lymphocyte with a unique antigen receptor that
enables recognition of invaders. The system is not only anticipatory as it also
remembers previous pathogen encounters that allow repelling a second invasion, or
quickly elimination of the recurrent invasion by activating a faster and stronger
immune response (Cooper, Alder 2006).
B-lymphocytes play an important role in establishing and maintaining the
protective immunity, as they produce antibodies, serve as antigen-presenting cells,
and have other regulatory functions (Cancro et al. 2009). B-cells can internalize the
antigen via the B-cell receptor so they can present it to T-cells effectively. They also
express costimulatory molecules so they can activate T-cells recognizing the same
antigen, and not only produce antibodies but also secrete cytokines such as
Interleukin-2 (IL-2), Interleukin-6 (IL-6) and Interleukin-12 (IL-12), IFN-γ, transforming
growth factor-β (TGF-β) and TNF-α (VanderLaan, Reardon 2005).
T-cells are an important piece in the machinery of adaptive immunity, as they
5

cover a wide range of functions essential to the defense of cells against pathogens,
such as helping in the maturation of B-cells, preventing auto-immunity and destroying
tumors and virally-infected cells. Antigen presenting cells (APCs), dendritic cells
(DCs), B-lymphocytes and macrophages present the antigen in the form of peptides
on their surface, in the groove of their major histocompatibility complex (MHC)
molecule for T- cells to recognize them.

Depending on their length (number of

residues) these peptides can be bound by either the MHC class I molecules (8-9
residue-peptides) commonly expressed across cell types or to MHC class II
molecules (13-17 residue-peptides) expressed by APCs only (Rudenski et al. 1991).
In MHC class I presentation the peptides presented are derived from endogenous
proteins that have been processed via a ubiquitin-driven proteolytic system. In MHC
class II presentation, the peptides presented are derived from exogenous proteins,
internalized via endocytosis and processed via the proteolytic system. Cytotoxic Tlymphocytes (CTLs) respond to specific epitopes presented through the MHC class I
pathway. Cluster-of-differentiation-4-positive (CD4+) T-cells respond to specific
epitopes presented through the MHC class II pathway (Gerloni et al. 2004).
T-cells may express either a αβ or γδ type of receptor for antigen recognition.
The αβ receptor recognizes peptides bound to MHC molecules. In contrast, the γδ
receptor is not as well understood (Chien, Boneville 2006), but is believed to take
part by constituting a bridge between innate and adaptive immune responses (Aljurf,
Ezzat & Mussa M. 2002). Cells bearing the αβ T- cell receptor (TCR) can be
subdivided into cytotoxic and helper T-cells. The latter express the CD4 molecule on
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their surface and secrete cytokines after interacting with antigens presented by MHC
class II molecules; they induce B-cells to proliferate and mature so they can produce
antibodies. The cytotoxic T-cells express cluster-of-differentiation-8 (CD8) on their
surface, and antigen presented by MHC class I molecules on a cell. Upon activation
CD8+ T-cells induce apoptosis of the target cell (Davis et al. 2003). Naïve CD4+ Tcells (i.e. CD-4+ T-cells that have not been exposed to antigen) differentiate into
various types of helper T-cells (Th), which can be Th1, Th2, Th17 and regulatory Tcells. Cytokines drive this differentiation into the different subtypes. Th1 cells produce
IFN-γ, TNF and IL-2, and are important in the defense against intracellular pathogens
(Wilson, Rowell & Sekimata 2009). Th2 cells mainly produce IL-4, IL-5 and IL-13 and
are important for antibody-mediated responses for defense against extracellular
parasites like helminthes. Th2 cells are also responsible for some allergic
inflammatory diseases such as asthma (Paul, Zhu 2010)(Wilson, Rowell & Sekimata
2009). The most recently discovered subset of CD4+ helper T-cells, Th17, is said to
be capable of promoting chronic inflammation and tissue damage (Cua, Tato 2010).
Th17 produce IL-17A, IL-17F, IL-21, IL-22 and human IL-26.They are believed to
contribute to defense against extracellular bacteria and fungi (Wilson, Rowell &
Sekimata 2009). Regulatory T-cells (Treg) have the ability to suppress inflammation
and induce tolerance by secreting the anti-inflammatory cytokine IL-10 and TGF- β,
and inhibit the proliferation of naïve T-cells as well as reduce the helper T-cells
responses(VanderLaan, Reardon 2005).
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1.4 Phosphorylation of STAT4
Signal transducer and activator of transcription 4 (STAT4) is a transcription factor
that is activated by IL-12, and that interacts with DNA sequences in the IFN-γpromoter region to increase this gene’s transcription (Figure 1). Several studies have
found that the activation of STAT4 also increases the expression of the IL-12
receptors and other cytokine receptors needed for the induction of IFN- γ (Morinobu
et al. 2002, Lawless et al. 2000). Upon presentation of an infectious antigen, Th1
cells secrete IFN- γ that induces apoptosis of infected cells, and it has been found
that IFN- γ produced by these CD4+ T-cells induces apoptosis in tumor cells (Komita
et al. 2006, Wang et al. 2003).Critical evidence for this is found in studies in which
tumor-bearing mice have been treated with an anti- IFN-γ monoclonal antibody. This
treatment inhibited antitumor activity completely (Komita et al. 2006). In fact in an
IFN- γ-capture assay experiment T-cells that secreted IFN- γ and were enriched in
vitro proved to have antitumor effectiveness in vivo, showing the strong immune
power of this cytokine (Becker et al. 2001). For this reason, it is important to screen
for possible inhibitors that may cause reduced signaling through STAT4 activation,
and as a consequence, reduced antitumor activity via IFN-γ secretion.

1.5 T-cells and tumor microenvironment
It is well known that the interactions of tumor cells and their microenvironment
have an effect on the tumor growth and metastasis. Inflammatory cells, tumor cells
and connective tissue cells all secrete cytokines that establish a complex network
and contribute to the number of factors present in the tissue (Ben-Baruch 2003). The
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presence of numerous cytokines can lead to a complex environment where the
immune cells may encounter stimulation and inhibition from different sources,
yielding results that cannot be modeled as easily due to the presence of main factors
that cause crosstalk of signaling pathways. One of the many factors that T-cells
respond to is IL-12. A known T-cell stimulatory factor and main driver towards Th1
differentiation, IL-12 is a heterodimer consisting of two disulfide subunits: p35 that is
similar in sequence to IL-6 and the granulocyte colony stimulating factor (G-CSF),
and p40 that is highly similar to the IL-6 receptor (IL-6R) and binds to the β2 subunit
in the IL-12 receptor (IL-12Rβ2)(Ling et al. 1995). IL-12-related species (IL-12p70
heterodimer, IL-12p40 monomer and IL-12(p40)2 homodimer) are produced mainly
by DCs, and such production depends on the exposure of the cell to inflammatory
mediators during differentiation and maturation (Klinke II 2006, Ebner et al. 2001).
Such mediators could be Interleukin-4 (IL-4), Interferon-γ (IFN- γ), and Prostaglandin
E2 (PGE2) as a few examples. The stimuli that immature DC receive in the
peripheral tissues leads to the production of more mediators such as IL-12, either in
its bioactive form, IL-12p70, or as the antagonizing forms that block the action of the
bioactive one , IL-12p40 and IL-12(p40)2 (Klinke II 2007). IL-12 activation and
stimulation leads to the activation of the Janus kinases Jak2 and Tyk2, which in turn
phosphorylate IL-12R, serving as docking sites for the transcription factor STAT4 to
be bound and phosphorylated; this is crucial in Th1 differentiation and the
consequent production of IFN-γ, and thus the consequent effective elimination of
pathogens and malignant molecules (Morinobu et al. 2002).
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Th17 cells differentiate form CD4+ T-cell precursors responding to TGF-β and IL6 stimulation, which means they are independent of STAT1 and STAT4 signaling (Lee
et al. 2009). The signaling of IL-6 is coupled to induction of IL-21 through signal
transducer and activator of transcription 3 (STAT3) activation, which favors the
development of Th17 cells (Zhou et al. 2007). Additionally, TGF-β has been shown
to stimulate Th17 cell development and to suppress Th1 and Th2 development by
means of inhibiting STAT4 signaling (Mathur et al. 2007). In developing Th17 cells,
the IL-23 receptor (IL-23R) is induced, whereas in Th1 cells the IL-12Rβ2 is the one
induced; activation of either of the receptors drives the fate of the helper T cell into
Th17 or Th1: the IL-12 receptor strongly activates STAT4 signaling and the IL-23
receptor strongly activates STAT3 signaling (Lee et al. 2009); (Mathur et al. 2007).
STAT4 signaling has been found to be a very important element in various diseases,
such as Sézary syndrome (i.e. cutaneous lymphoma) where the absence of the IL12Rβ2 leads to reduced STAT4 activation and has been correlated to the disease
progression (Showe et al. 1999). It has also been identified as a key component for
the mechanism of action of Chitosan-IFN-γ-pDNA Nanoparticle (CIN) therapy for the
treatment of allergic asthma (Kumar et al. 2003).
Besides IL-23, it has been established that IL-6 promotes the differentiation of
naïve T-cells into B-lymphocyte T helper cells, by leading to secretion of IL-21,
independently of Th1, Th2, or Th17 functions. It has also been established that IL-6
in combination with TGF-β prompt the development of Th17 cells via STAT3
activation (Eddhari et al. 2009). It is known that IL-17 stimulates production of IL-6 in
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T cells and fibroblasts through a positive-feedback loop (Ogura et al. 2008) and Th17
cells are believed to promote tumor growth by producing IL-17 that promotes STAT3
activity and leads to up-regulation of antiapoptotic (i.e. prevent cell’s programmed
death) and angiogenic (i.e. promote development of vessels) genes (Wang et al.
2009). In fact, IL-6 has been correlated to resistance to therapy and drug-induced cell
death in multiple myeloma (Burdelya et al. 2002, Frassanito et al. 2001). Additionally,
STAT3 responds to IL-6 (Figure 1) by becoming phosphorylated and translocated to
the nucleus to serve as transcription factor for the suppressor of cytokine signaling 3
(SOCS3), which competes with STAT4 for binding to the IL-12R, and to the Janus
kinase 2 (JAK2) that phosphorylates STAT4(Yamamoto et al. 2003). Thus, it can be
said that stimulation of IL-6 may lead to reduced Th1 immune response by downregulating STAT4 signaling.
A well known strategy for tumor cells to evade immunosurveillance is the downregulation of cell surface molecules involved in immune recognition, and the
overexpression of the immunosuppressive cytokine TGF-β. This cytokine is
overexpressed by many tumor cells, and it enhances the generation of
immunosuppressive regulatory T-cells that also produce TGF-β (Nam et al. 2008). In
addition TGF-β is known to inhibit Th1 responses by shifting T cells towards a Th2
type, which results in a less efficient immune response against tumor cells (Flavell et
al. 2010)(Maeda, Shiraishi 1996). The TGF-β receptor is composed of type I and
type II receptor serine/threonine kinases on the T-cell surface. After binding of TGF-β
receptor II phosphorylates receptor I activating it to initiate signaling by
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phosphorylating Smad and leading to the activation of other kinases (Figure 2)(Shi,
Massague 2003). TGF-β is also known to inhibit IL-12 signaling in T-cells by
decreasing the activity of kinases involved in the activation of transcription factors
such as STATs(Bright, Sriram 1998).

Figure 1: Schematics of STAT signaling
A. Signal transducers and activators of transcription (STAT) proteins are tyrosine
phosphorylated via Janus kinases (JAKs) at around residue number 700 as a result of
cytokine-receptor stimulation. STATs also receive stimuli from other receptors in an indirect
way. B. Phosphatases (a) and supressors of cytokine signaling (SOCS) (b) can block STAT
access to tyrosine kinase at the receptor, mediate STAT dephosphorylation (c) mediate
interactions with protein inhibitors of STATs (d) or interfere with transcription by binding DNA
sequence or activated STAT protein. Source:(Levy, Darnell Jr. 2002).

Upon stimulation with insulin, its binding to the insulin receptor triggers the tyrosine
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kinase activity of the latter, initiating an intracellular signaling cascade where many mitogenactivated protein kinases (MAPKs) are activated, and the insulin receptor 1 (IRS-1) is the first
intracellular protein to be phosphorylated (Orcy et al. 2005)(Sykiotis, Papavassiliou 2001). As
insulin binds its receptor on the cell-surface, the latter becomes autophosphorylated in its βsubunits and this confers the receptor with tyrosine kinase abilities that phosphorylated insulin
receptor subtrates-1 and-2 (IRS-1 and IRS-2, respectively) (Figure 3). These phosphorylation
events generate docking sites for molecules such as phosphatidylinositol-(PI)-3-kinase among
others, leading ultimately to the stimulation of the MAPK/ERK kinase (MEK) and ERK
(Desbois-Mouthon et al. 1998). It is known that phosphorylation of p38 MAPK and c-Jun Nterminal kinase (JNK) favors T-cell polarization toward Th1, and phosphorylation by
extracellular-signal regulated kinases (ERK) leads to polarization of T-cells toward Th2(Viardot
et al. 2007, Dong, Davis & Flavell 2002). As a consequence, continuous activation of the
insulin pathway that would cause activation of ERK and inhibition of p38 and JNK, would lead
to favored polarization into Th2 cells, decreasing the IFN-γ to IL-4 ratio as a consequence of
decreased phosphorylation of STAT4 (Viardot et al. 2007). However it is not clear yet whether
insulin exerts an inhibitory effect on IL-12 signaling since its role as an inhibitor remains
relatively unknown.
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Figure 2. Signaling events downstream of TGF-β association to receptor
Receptor type II initiates the signaling cascade by phosphorylating receptor I followed by the
subsequent activation of Smad proteins. Smad 7 regulates signaling by binding to the receptor
and causing its degradation. Source:(Izzi, Attisano 2004).

Figure 3. Signaling events upon insulin binding at cell surface
As insulin binds the receptor, the latter becomes activated and phosphorylates insulin
receptor substrates-1 and-2 initiating a cascade that activates MAP kinases. Source:
http://sigmaaldrich.com
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Based on all this evidence suggesting crosstalk of different signaling pathways, it
was hypothesized that the presence of either TGF-β, IL-6 or insulin at high levels in
the cell’s environment would lead to decreased STAT4 phosphorylation and in
consequence, a less functional helper T-cell. The objective of this work was to
develop an assay to study the effect of some of these factors encountered in tumor
microenvironment on the immune response of Th1 cells via STAT4 activation, and to
establish the significance of the presence or not of such crosstalk in the immune
system.
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CHAPTER THREE:
MATERIALS AND METHODS
3.1 Cell lines and tissue culture
The cell line 2D6, a Th1-cell clone from mice, was kindly provided by Dr. M.
Grusby (Harvard University, Cambridge, MA, U.S). The cells were kept in 25 cm2
tissue culture flask with 15ml cell culture media and supplemented with or without
6.7ng/ml recombinant Mouse IL-12p70 (eBioscience, San Diego, CA, U.S.). The
tissue culture media consisted of RPMI-1640 supplemented (sRPMI) with 10% Fetal
Bovine Serum (FBS) (Atlanta Biologicals, Lawrenceville, GA, U.S.), 100 I.U./ml
Penicillin/Streptomycin, (Biowhittaker, Walkersville, MD, U.S.), 1% of 200mM LGlutamine (Mediatech, Manassas, VA, U.S.), 1% of Non-Essential Amino Acids 100X
(Chemicon International, Temecula, CA, U.S.A.), 1% of 100mM Sodium Pyruvate
(MP Biomedicals, Solon, OH, U.S.A.), 1% of 1M HEPEs

(Fisher Bioreagents,

Pittsburgh, PA, U.S.), and 2μl of b-mercaptoethanol (Sigma Chemical, St. Louis, MO,
U.S.). Tissue culture media was replaced every 24 hours and cells were cultured at
37ºC with 5% CO2.

3.2 Antibodies and Reagents
Purified Hamster Anti-Mouse IL-12 Receptor B2, Fluorescein isothiocyanate
(FITC)-conjugated Mouse Anti-Armenian and Syrian Hamster IgG1 (G94-56), Alexa
Fluor 647-conjugated Mouse Anti-Stat4 (pY693), Alexa Fluor 488 Mouse anti-Stat3
(pY705), BD Phosflow lyse/fix buffer 5X, and BD Phosflow Perm Buffer III were
purchased from BD Biosciences (San Diego, CA, U.S.). ChromPure Mouse IgG
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(whole molecule) and ChromPure Rat IgG (whole molecule) were purchased from
Jackson Immuno Research (West Grove, PA, U.S.). DPBS 1X and RPMI-1640 were
purchased from Mediatech (Manassas, VA, U.S.). Sodium Azide (Na Azide) was
purchased from United States Biochemical Corp (Cleveland, OH, U.S.).

3.3 Stimulation of IL-12 signaling
IL-12 and/or other cytokine stimulation: Cells were cultured in 96-well U -bottom
plate for 12 hours with sRPMI media without IL-12 before stimulation, at a cell density
of 6 x 104 cells/well. Either different concentrations of IL-12 (10, 40 and 100 ng/ml) or
10 ng/ml of IL-6, TGF-β or insulin (each alone or together with 40 ng/ml of IL-12),
were added into IL-12 treatment groups 12 hours later, DPBS was added into
negative controls. The cells were cultured for 15 minutes, 1 and 2 hours, and
samples at time --12 hours (before IL-12 depletion) and time 0 (after 12 hours of IL12 depletion) were collected.
For all situations, at each time point (-12 hours, 0 hours, 15 minutes, 1 hour,
2 hours) supernatant for each well was taken and stored at -20ºC. Pre-warmed
Phosflow lyse/fix buffer was added into each well and incubated at 37 ºC for 10
minutes. Then, 200 μl of DPBS were added into each well. The plates were stored at
4 ºC until stained for flow cytometry. The experiment was performed in triplicate, cells
were cultured at 37ºC, and 5% CO2.

3.4 Flow cytometry
Flow cytometry is a technique used to analyze large numbers of cells in short
time (~10,000 cells/s) that relies on hydrodynamic focusing to inject the cell
suspension into a sheath stream inside a flow cell (Rieseberg et al. 2001). A laser
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beam is directed toward the cell and the light scattered in all directions is collected by
filters and detectors. The voltage pulses generated by the light scattering are counted
and correlated to cell size (small angle of forward scatter) and internal complexity
and granularity of the cell (large angle or side scatter). Hydrodynamic focusing
ensures that only one cell at a time passes through the laser beam. Fluorophores
can be used to label molecules such as antibodies specific to molecules within the
cell or on its surface as the appropriate laser wavelength will excite it and cause it to
emit light that can be detected as well.
Treated cells were prepared, as described in 3.3, and stained with proper
fluorophore-conjugated antibodies specific for IL12RB2 and phosphorylated STAT4
(pSTAT4).
Treated cells were permeabilized by incubating them with chilled Phosflow Perm
Buffer III for 30 minutes on ice, and subsequently washed twice with ice cold PBSAZ.
Cells were incubated with ChromPure Mouse IgG and ChromPure Rat IgG (Block
Reagent) on ice for 15 minutes to block non-specific IgG binding sites. Subsequently,
the cells were washed with PBSAz once, incubated with appropriate antibodies
conjugated to a fluorophore (Table 1) for 30 minutes in the dark and at room
temperature. The same process was repeated for all selected antibodies. Finally, the
cells were washed with PBSAz three times and transferred into 5ml tubes containing
PBSAz for flow cytometry analysis. No stain controls were used as negative flow
cytometry controls, and single stained controls were used to assess the fluorescence
spill over. To make up for any possible spectral overlap of the fluorescence excitation
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and emission spectra for the fluorophores used, the spectral spillover was estimated
as shown in the spillover matrix (Table 2). These values were calculated from singlestained controls as described by Klinke (Klinke, Brundage 2009). The spillover matrix
was used to correct raw fluorescent intensity observed in cells stained with more than
one fluorophore, so that the scatter plots of single stained controls after spectral
overlap were removed using the compensation matrix. Unstained controls provided
an estimate of background fluorescence for all the channels. So for instance, after
compensation for spectral analysis, the sample stained with a fluorescently labeled
antibody against phosphorylated STAT4 (Alexa Fluor-647) should show an increase
above background only for the pSTAT4 channel.

Table 1. Fluorescence spectra of fluorophores used.
Fluorophore

Excitation peak (nm)

Emission peak (nm)

FITC

495

520

Alexa Fluor 647

650

668

Table 2. Spillover matrix of FITC and Alexa Fluor 647 channels.
FITC (IL-12Rβ2)

Alexa Fluor 647 (pSTAT4)

FITC (IL-12Rβ2)

1

0

Alexa Fluor 647 (pSTAT4)

0

1

Data Analysis

The flow cytometry raw data were analyzed with R/Bioconductor (see Appendix
A) to obtain compensation and transformed values of the median fluorescent
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intensities for each parameter measured (i.e. pSTAT4).
A two-way ANOVA was applied at each time point to compare the effect of each
potential inhibitor to the effect of IL-12 on pSTAT4 median fluorescent values and live
cell percent values. P≤ 0.05

was taken as a point of significance. The statistical

analysis was done with the Minitab 15 Statistics Software.

3.5 Western Blot

The Western Blot technique allows the detection of proteins from a tissue or
extract sample by molecular weight. Cells are broken by mechanical methods such
as sonication and detergents and buffers are used to lyse them and solubilize the
protein sample. The proteins are then separated by gel electrophoresis mostly
sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE), in which
reducing agents are used to denature proteins by removing secondary and tertiary
structures. The SDS is negatively charged and coats the protein to protect its
denatured structure, and so the protein migrates through the acrylamide gel towards
the positively charged electrode. The samples are loaded onto the gel into wells, and
when voltage is applied the proteins migrate at different velocities according to size
(i.e. smaller molecular weight proteins migrate faster) separating into bands on a
lane. Once separated, the proteins are transferred onto a nitrocellulose or
polyvynilidene difluoride (PVDF) membrane by means of an electric current that pulls
the proteins into the membrane in the exact same location and distribution they had
within the gel. The membrane is blocked with a generic protein such as bovine serum
albumin (BSA) or non-fat dry milk to avoid unspecific binding of antibodies used for
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detection to the membrane. For detection the membrane is incubated overnight at
cold temperature in a dilute solution of primary antibody from an animal source that is
specific to the protein of interest. The membrane is then washed and incubated in a
dilute solution of secondary antibody directed toward the species of origin of the
primary antibody. The secondary antibody is usually linked to an enzyme that cleaves
a chemiluminescent agent so the bound complex can be detected by film exposure.
Some other secondary antibodies are bound to a fluorophore or fluorescent label so
a scanner with a CCD camera (i.e.photosensor) that has appropriate emission filters
can capture a digital image of the membrane for analysis.

Cells were cultured and treated as explained on section 3.3 for stimulation with
each potential inhibitor (TGF-β, insulin, IL-6) at a cell density of 6 x107/ml. Cells were
pelleted and resuspended in 1 ml of cold DPBS. Then the cell suspension was
centrifuged for 30 seconds and pelleted again, and the pellet was resuspended in
500 μl of cold Cell Lysis Buffer (90% double distilled water, 2% 1M Tris (pH 7.66), 3%
5M NaCl, 0.2% 0.5M EDTA, 1% 0.1M EGTA, 1% Triton X-100, 2.5 % 0.1M Sodium
pyrophosphate, 0.5% Sodium orthovanadate, 2.5% 1mg/ml leupeptin) and incubated
on ice for 5 minutes. Cells were then sonicated 4 times for 5 seconds each, and
centrifuged for 10 minutes at 4°C. The supernatants were transferred to new tubes
(around 250 μl per tube) and the lysates were stored at -70°C. The lysates were
loaded onto an acrylamide gel together with a Stat3 control cell extract (Cell
Signaling Technology, Inc.) and a molecular weight marker (Odysssey Two-Color
Protein Molecular Weight Marker, Li-Cor Biosciences, Lincoln, Nebraska, USA). The
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lysates were separated by gel electrophoresis and blotted onto a PVDF membrane
(see Appendix D). The membrane was blocked with Odyssey® Blocking Buffer (LiCor Biosciences, Lincoln, Nebraska, USA) and probed with antibodies against
pSTAT3 and an antibody against glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as a loading control (GAPDH (FL-335), Santa Cruz Biotechnology, Inc.,
Santa Cruz, California, USA). Phosphorylated STAT3 was detected by use of a rabbit
anti-Phospho STAT3 (Y705) (Cell Signaling Technology, Inc.) primary antibody, and
IRDye® 800CW Conjugated Goat (polyclonal) anti-rabbit IgG secondary antibody.
The proteins were imaged with the Odyssey® Infrared Imaging System (Li-Cor
Biosciences, Lincoln, Nebraska, USA).
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CHAPTER FOUR:
RESULTS AND DISCUSSION

4.1 Effect of potential inhibitors on STAT4 phosphorylation

In order to address the response of T cells to the presence of possible inhibitors in
the tumor microenvironment, the 2D6 cell line derived from a mouse Th1 cell clone
was cultured at a cell density of 6 x 104 cells/well and deprived of IL-12 for a period of
12 hours. Following this period of starvation, they divided into four treatment groups:
treated with IL-12 only, treated with the potential inhibitor of STAT4 phosphorylation
(i.e. TGF-β, Insulin, IL-6) only, treated with both insulin and the potential inhibitor, or
with no treatment. The appropriate cells were stimulated with either 10 ng/ml TGF-β
(Zheng et al. 2002),(Hanafusa et al. 1999), 10 ng/ml insulin (Viardot et al. 2007) or 10
ng/ml IL-6 (Nakagawa et al. 2009)(Takeda et al. 1998) for 15 minutes, 1 hour or two
hours. The results are representative of at least two biological replicates.

4.1.1 Gating for cell population

To exclude dead cells and non-cellular debris from the flow cytometric analysis, the
forward and side scatter characteristics of the observed events for each sample was
used to identify live cells by means of R/Bioconductor analysis. Reduced cell size
(i.e., reduced forward scatter) and an increase in cellular granularity (i.e., an increase
in side scatter) correlate with cell death. As a representative sample, the forward and
side scatter plot for cells at -12 hours (i.e. cells before IL-12 depletion) is shown in
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Figure 4. Live cells used in subsequent analysis were identified using a data-driven
gate as enclosed by the red circle: the blue dots stand for each individual cell, the red
circle encloses 95% of the population used for subsequent analysis.

Figure 4. Forward and side scatter of 2D6 cells at time -12 hours (i.e. before IL-12
starvation).

Blue dots represent individual cells, and 95% of the population used for analysis is
enclosed in the red circle.
4.1.2. Response of 2D6 cells to cytokine stimuli
To assess for the optimal dose of IL-12 to obtain a maximum response of the IL12 signaling pathway in 2D6 cells, the activation of STAT4 was measured after
stimulation with different concentrations of IL-12. Such parameter was measured by
flow cytometry using an antibody for the phosphorylated STAT4 (Table 1). The
optimal concentration determined was used in subsequent experiments.
Since the levels of expression of IL-12Rβ2 correlate positively with STAT4
activation upon IL-12 stimulation as found in a previous study from our research
group (Finley et al. 2010), the presence of IL-12Rβ2 was observed in each
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experiment as a internal control by flow cytometry using the appropriate antibodies
(Table 1).
A statistical data-driven threshold was used to define the background level of
fluorescence associated with IL12R β2 and pSTAT4, using unstained cells, and
single stain controls for each (See Appendix B). The positive thresholds for IL12R β2
and pSTAT4 were defined as the level of fluorescence for which 95% of the unstimulated cells exhibited a lower level of fluorescence. In general the distribution in
Median fluorescent Intensities (MFIs) associated with IL12Rβ2 and pSTAT4 exhibited
unimodal distributions, as depicted by the single-stain controls used for the
thresholds (Figure 6). Median value of these unimodal distributions were
subsequently used to summarize dynamic changes in components of the IL-12
signaling pathway.
Following IL-12 starvation for 12 hours, samples were collected from the
treatment groups at 0, 15 minutes, 1 and 2 hours. A representative scatter plot of the
Median fluorescent Intensity (MFI) for pSTAT4 versus IL12Rβ2 is shown in Figure 6
where the MFI associated with phosphorylated STAT4 was correlated with IL12Rβ2
positive cells.

Dose response

In order to establish the concentration of IL-12 to treat the 2D6 cell, a dose response
was done, to evaluate the concentration for which the maximum STAT4 activation
was obtained (Figure 5). Based on that, and previous findings, the concentration of
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IL-12 used across all the experiments was 40 ng/ml.

Figure 5. Dose response curve.
Response values were recorded using different concentrations of IL-12, where the response
(R) corresponds to phosphorylated STAT4 upon IL-12 stimulation of 2D6 T-cells.

Figure 6. Single stain control histograms.
The left panel shows the histogram for pSTAT4 mean fluorescent intensity (MFI), where MFI
of pSTAT4 is the x-axis and normalized cell density is the y-axis. The right panel shows the
histogram for IL-12Rβ2 mean fluorescent intensity (MFI), where MFI of IL-12Rβ2 is the x-axis
and normalized cell density is the y-axis. The gray polygon represents no stain control (i.e.
6x104 cells/well treated with IL-12 and no fluorescent stain), the red line represents the single
stain control for pSTAT4 (i.e. 6x104 cells/well treated with IL-12 and Alexa Fluor 647 antipSTAT4 antibody), and the black line represents the single stain control for IL-12Rβ2 (i.e.
6x104 cells/well treated with IL-12 and FITC anti- IL-12Rβ2 antibody).
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Figure 7. Representative plot of phosphorylated STAT4 versus IL-12Rβ2 upon
stimulation with 40 ng/ml of IL-12 for 1 hour.
The scatter plot (C) represent the cell population distribution for expression of pSTAT4 and IL12R β2. The vertical solid line represents the positive threshold for IL-12R β2 expression
observed as the vertical dashed line in panel A, and the horizontal dashed line represents the
positive threshold for pSTAT4 expression observed as a vertical dashed line in panel B. cells
positive for both molecules appear in the upper right quadrant of panel C.

4.1.3. Effect of TGF-β on STAT4 phosphorylation

The time course in the expression of pSTAT4 in 2D6 cells upon stimulation with
TGF-β is depicted in Figure 8. In general the most significant effect with respect to
the unstimulated group was observed in the cells stimulated with TGF-β (Table 3)
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particularly after two hours of incubation (See Appendix C). A decreasing trend in
STAT4 phosphorylation is followed after 15 minutes and continues with time in the
group treated with TGF-β only, comparable to the trend followed by the unstimulated
group. The lowest value of phosphorylation of STAT4 was reached by the latter after
2 hours of incubation (mean=44.08). The highest MFI values are displayed by the
group treated with IL-12 and TGF-β, reaching a peak of STAT4 activation at 1 hour
(mean=106.36) followed by a subtle decrease at 2 hours (mean=101.15). A similar
trend was observed for the group treated with IL-12 only, where stimulation by this
cytokine proved to have a significant effect as well on STAT4 phosphorylation (Table
3).

Figure 8. Time course of pSTAT4 expression in different treatment groups with TGF-β.
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of TGFβ (cross marks), 40 ng/ml of IL-12 ( triangles), with both TGF-β and IL-12(squares) or left
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours.
Means of MFI values of pSTAT4 are shown above.
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Table 3. P-values from two-way ANOVA for analysis of TGF-β experiments.
STAT4 phosphorylation

Cell viability

Time

IL-12

TGF-β

Interaction

IL-12

TGF-β

Interaction

15 min

<0.001

0.031

0.077

0.237

0.939

0.265

1 hour

0.136

0.262

0.605

0.758

0.014

0.12

2 hours

<0.001

<0.001

<0.001

0.011

0.001

0.005

Figure 9. Median fluorescent intensities of pSTAT4 per time point.
The bars represent the MFI values of phosphorylated pSTAT4 at each time point for each of
the treatments: cells stimulated with 10 ng/ml of TGF-β (diagonal-line pattern), 40 ng/ml of IL12 (yellow, no pattern), with both TGF-β and IL-12(plaid pattern) or left untreated (dotted
pattern), and allowed to remain in culture for the indicated times. Means of MFI values of
pSTAT4 are shown above. The asterisks show the time points at which significant differences
with respect to the unstimulated group were observed (Table 3).

Effect of TGF-β on cell viability

The time course in the viability of the 2D6 treatment groups is depicted in Figure
10. The values of cell viability (i.e. live cell percent) were analyzed for each time
point to compare across treatments. In general all treatment groups displayed a
subtle decreasing trend in viability with increasing time, except for the untreated
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group where a peak in live cell percent was observed at 1 hour after time 0 (mean=
29.05). The lowest mean value for live cell percent was reached by the group treated
with TGF-β only after 2 hours (mean=5.27) (Figures 10,11).

Figure 10. Time course of cell viability in different treatment groups of TGF-β.
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of TGFβ (cross marks), 40 ng/ml of IL-12 ( triangles), with both TGF-β and IL-12(squares) or left
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours.
Means of live cell percent values are shown above.

Figure 11. Cell viability per time point.
The bars represent the values of live cell percent at each time point for each of the
treatments: cells stimulated with 10 ng/ml of TGF-β (diagonal-line pattern), 40 ng/ml of IL-12
(yellow, no pattern), with both TGF-β and IL-12(plaid pattern) or left untreated (dotted pattern),
and allowed to remain in culture for the indicated times. Means of live cell percent values are
shown above. The asterisks show the time points at which significant differences with respect
to the unstimulated group were observed (Table 3).
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4.1.3.1. Discussion

Transforming growth factor-β has been previously shown to inhibit IL-12
signaling (Bright, Sriram 1998, Pardoux et al. 1999). Pardoux et al. observed that
treatment with TGF-β for 20 minutes inhibited STAT4 phosphorylation significantly in
human T-cells, the same Bright and Sriram found in mouse T-cells. However, in the
present study the strongest inhibitory effect of TGF-β was observed after incubation
for 2 hours suggesting that time frame for the effect of this protein on the model cell
line used may be longer than in vivo. Other STAT proteins like STAT1 exhibit rapid
activation and deactivation kinetics with a half life of approximately 15 minutes(Lim,
Cao 2006). The results in this study show that stimulation with IL-12 yields a peak of
pSTAT4 after an hour of incubation (Figure 8). This observed delay in the stimulatory
effects of IL-12 may be common to other effects in this cell line, or it is possible that
TGF-β has a delayed onset of action in these cells. However the inhibitory effect was
observed only in the cells stimulated with TGF-β only, not in the ones stimulated with
both TGF-β and IL-12, in fact, the highest STAT4 activation was accomplished in the
by this group suggesting a synergistic effect of TGF-β and IL-12 in the 2D6 cells.
Bright and Sriram conducted a study on the effect of TGF-β on murine T-cells, and
found that it inhibited the activity of Janus kinase-2 (JaK-2) and Tyrosine kinase-2
(Tyk-2) to a great extent, causing the inhibition of STAT4 phosphorylation as well
(Bright, Sriram 1998). However, Sudarshan et al found that TGF-β had no effect on
the activation of JaK-2 and Tyk-2, and did not inhibit STAT4 phosphorylation by these
kinases (Sudarshan et al. 1999).

The TGF-β ligand starts signaling by bringing
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together type I and type II receptor serine/threonine kinases as it binds them at the
surface of the T-cell. Receptor II phosphorylates the kinase domain in receptor I and
the activated receptor subsequently phosphorylates Smad proteins (Shi, Massague
2003). Active STAT4 promotes the expression of Smad7, a regulatory protein that
antagonizes TGF-β signaling (Letterio 2005, Soto, Price-Schiavi & Carraway 2003).
This would explain the observed synergy between IL-12 and TGF-β. An increase on
Smad 7 in 2D6 cells upon stimulation with IL-12 would support the hypothesis.
Another interesting effect observed after incubation with TGF-β was the
increased reduction of cell viability after 2 hours of incubation with TGF-β only
(Figure 9). TGF-β has been linked to apoptosis in several studies. The mechanism of
action includes the expression of cyclin-dependent kinases (CDKs) that inactivate
proteins important for cell survival, and the expression of death-associated protein
(DAP) kinase (Jang et al. 2002). The increased variability in the effects after 2 hours
of TGF-β alone (Figure 9 and Appendix C) on both STAT4 activation and viability may
be a result of the extensive amount of cross-talk that takes place in TGF-β signaling
once it reaches the level of Smads (Massague 2000). This cross-talk is additionally
enhanced by the cooperative actions of Smads in the nucleus for the transcription of
several target genes that are transcribed depending on the cell type and its metabolic
needs (Jang et al. 2002). Observing changes in associated signaling proteins may
help inform on the mechanisms that TGF-β uses to promote apoptosis.
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4.1.4. Effect of insulin on STAT4 phosphorylation

The time course in the expression of pSTAT4 in 2D6 cells upon stimulation with
insulin is shown in Figure 12. The MFI values of STAT4 phosphorylation were
analyzed for each time point to compare across treatments (see Appendix C),
Significant differences with respect to the unstimulated group were observed mainly
due to IL-12 stimulation at all time points (Table 4). Insulin only had a significant
effect on 2D6 cell after 1 hour of treatment and in the presence of IL-12, while the cell
group stimulated with insulin only displayed a very similar trend to the unstimulated
group maintaining close MFI values through the 2 hours. The highest MFI value for
STAT4 activation was observed after 1 hour of incubation in the group treated with IL12 and insulin (mean=94.9) (Figure 13).

Figure 12. Time course of pSTAT4 expression in different treatment groups with insulin
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of
insulin (cross marks), 40 ng/ml of IL-12 ( triangles), with both insulin and IL-12(squares) or left
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours.
Means of MFI values of pSTAT4 are shown above.
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Table 4. P-values from two-way ANOVA for analysis of insulin experiments.
STAT4 phosphorylation

Cell viability

Time

IL-12

Insulin

Interaction

IL-12

Insulin

Interaction

15 min

0.016

0.694

0.141

0.311

0.995

0.379

1 hour

<0.001

0.033

0.005

0.197

0.043

0.606

2 hours

<0.001

0.484

0.002

0.106

0.374

0.048

Figure 13. Median fluorescent intensities of pSTAT4 per time point.
The bars represent the MFI values of phosphorylated pSTAT4 at each time point for each of
the treatments: cells stimulated with 10 ng/ml of insulin (diagonal-line pattern), 40 ng/ml of IL12 (yellow, no pattern), with both insulin and IL-12(plaid pattern) or left untreated (dotted
pattern), and allowed to remain in culture for the indicated times. Means of MFI values of
pSTAT4 are shown above. The asterisks show the time points at which significant differences
with respect to the unstimulated group were observed (Table 4).

Effect of insulin on cell viability

.All treatment groups exhibited a subtle increase in viability at 1 hour followed by a
decrease except for the untreated group where the live cell percent continued to
increase in time(Figures 14, 15). The highest percent of live cells was observed at 1
hour in the group treated with both insulin and IL-12 (mean=33.62). In general
treatments no effect on cell viability, except for the group treated with insulin where
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statistically significant difference with respect to the unstimulated group was
observed (Table 4).

Figure 14. Time course of cell viability in different treatment groups of insulin
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of
insulin (cross marks), 40 ng/ml of IL-12 ( triangles), with both insulin and IL-12(squares) or left
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours.
Means of live cell percent values are shown above.

Figure 15. Cell viability per time point.
The bars represent the values of live cell percent at each time point for each of the
treatments: cells stimulated with 10 ng/ml of insulin (diagonal-line pattern), 40 ng/ml of IL-12
(yellow, no pattern), with both insulin and IL-12(plaid pattern) or left untreated (dotted pattern),
and allowed to remain in culture for the indicated times. Means of live cell percent values are
shown above. The asterisks show the time points at which significant differences with respect
to the unstimulated group were observed (Table 4).
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4.1.4.1 Discussion

In the present study the relationship between stimulation with insulin and IL-12
signaling in the Th1 cell line, 2D6, was shown for the first time. Viardot et al. found
that insulin promoted Th2 differentiation by reducing the IFN-γ (i.e. cytokine produced
by Th1 cells) to IL-4 (i.e. cytokine produced by Th2 cells) ratio in vitro in human
peripheral blood mononuclear cells (PBMC)(Viardot et al. 2007). These findings
coincide with a reduction in STAT4 phosphorylation in the 2D6 cell line after
incubating with insulin only for 1 and 2 hours. However, the fact that an up-regulating
effect in STAT4 phosphorylation was observed in the present study after 15 minutes
and 1 hour of incubation, it is possible that insulin participates in a pathway that
cooperates synergistically with IL-12 to activate STAT4. However, considering the
activation of STAT4 peaks at 1 hour across treatment groups and then decreases
and that in Viardot’s study the cells were treated for 72 hours, it is possible that a
more pronounced effect may be observed with the 2D6 cells in culture with insulin
within a larger time frame.
A similar increasing trend peaking at 1 hour was observed for the cell viability.
Although to a subtle extent, the increased viability is in agreement with Viardot’s
observations of insulin inhibiting apoptosis in CD4+ T-cells (Viardot et al. 2007). This
is also consistent with another study on cells from a murine T-cell line, A1.1, where
up-regulated levels of IRS-1 correlated with an inhibition of apoptotic signaling events
due to activation-induced cell death (AICD) (Li et al. 2002)and with the inhibition of
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apoptosis observed in vascular smooth muscle cells(Allen et al. 2005). In general,
future experiments increasing the exposure time are recommended to observe the
effects of insulin over a larger time frame.

4.1.5. Effect of IL-6 on STAT4 phosphorylation
Based on knowledge about the degree of homology between STAT3 and STAT4
the 2D6 cell line was also used to identify signaling cross-talk between IL-12 and IL6. (Levy, Darnell Jr. 2002); (Zhong, Wen & Darnell 1994)Phosphorylation of STAT4
was used as an indication of IL-12 activation while pSTAT3 was used as a positive
control for IL-6 activation. Unfortunately no pSTAT3 was observed in response to IL-6
stimulation (data not shown). In general there was no significant effect of IL-6 on the
2D6 cells at any time point, and the only significant differences with respect to the
unstimulated group were due to treatment with IL-12 after 1 and 2 hours of
incubation(Table 5) (Figures 16, 17). There was no significant effect of IL-12 or IL-6
on viability in these experiments (Table 5).
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Figure 16. Time course of pSTAT4 expression in different treatment groups with
insulin.
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of
insulin (cross marks), 40 ng/ml of IL-12 ( triangles), with both insulin and IL-12(squares) or left
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours.
Means of MFI values of pSTAT4 are shown above.

Table 5. P-values from two-way ANOVA for analysis of IL-6 experiments.
STAT4 phosphorylation

Cell viability

Time

IL-12

IL-6

Interaction

IL-12

IL-6

Interaction

15 min

0.946

0.075

0.364

0.994

0.798

0.477

1 hour

0.027

0.794

0.001

0.103

0.092

0.195

2 hours

0.035

0.167

0.003

0.423

0.21

0.129
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Figure 17. Median fluorescent intensities of pSTAT4 per time point.
The bars represent the MFI values of phosphorylated pSTAT4 at each time point for each of
the treatments: cells stimulated with 10 ng/ml of IL-6 (diagonal-line pattern), 40 ng/ml of IL-12
(yellow, no pattern), with both IL-6 and IL-12(plaid pattern) or left untreated (dotted pattern),
and allowed to remain in culture for the indicated times. Means of MFI values of pSTAT4 are
shown above. The asterisks show the time points at which significant differences with respect
to the unstimulated group were observed (Table 5).

Figure 18. Time course of cell viability in different treatment groups of IL-6.
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of IL-6
(cross marks), 40 ng/ml of IL-12 ( triangles), with both IL-6 and IL-12(squares) or left
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours.
Means of live cell percent values are shown above.
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Figure 19. Cell viability per time point.
The bars represent the values of live cell percent at each time point for each of the
treatments: cells stimulated with 10 ng/ml of IL-6 (diagonal-line pattern), 40 ng/ml of IL-12
(yellow, no pattern), with both IL-6 and IL-12(plaid pattern) or left untreated (dotted pattern),
and allowed to remain in culture for the indicated times. Means of live cell percent values are
shown above. The asterisks show the time points at which significant differences with respect
to the unstimulated group were observed (Table 4).

4.1.5.1 Discussion

The lack of observed pSTAT3 in the experiments in this study lead to a first
conclusion about the phosphorylation of STAT3: based on the degree of homology of
STAT3 and STAT4 it was possible that all the phosphorylated STAT3 was being
bound by the pSTAT4 antibody. This together with the fact that inhibiting effects of IL6 in the present study appear to be more subtle than expected, lead to ask the
question of whether STAT3 was being activated upon stimulation with IL-6 or not.
Western Blot experiments performed as indicated (See Appendix D) were conducted
to observe the phosphorylated STAT3 in the 2D6 cells after treatment with IL-6 and/or
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IL-12 (Figure 17). The fact that no phosphorylated STAT3 was observed after the
Western Blot experiments suggested that STAT3 was not being activated at all by IL6 in these cells. Ahn et al (Ahn et al. 1998)observed phosphorylated STAT3 in 2D6
cells upon stimulation with IL-12; however, considering the responsiveness of the cell
line to this interleukin, it is possible that the STAT3 observed was STAT4 that was
bound non-specifically. A possible explanation could be that pSTAT3 is being
deactivated before detection by cross-talk with an inhibiting pathway or could be all
activated by IL-12 prior to the experiment.

Figure 20. Western blot to observe pSTAT3 in 2D6 cells upon treatment with IL-6.
Cells were treated as they were for the previous experiments (see Materials and Methods)
and lysed for protein separation by gel electrophoresis. The gel was blotted onto a membrane
that was probed with antibodies against phosphorylated STAT3 (See Appendix D).

Sengupta et al. found that in human myeloid cells the phosphorylation of STAT3
was inhibited within 5 minutes upon IL-6 stimulation by the action of MEK and ERK
kinases that act by blocking the signaling pathway upstream of STAT3 activation
(Sengupta et al. 1998). It is possible that the MEK-ERK signaling pathway is being
activated and is inhibiting phosphorylation of STAT3 as an early event during the
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incubation time.
The IL-6 receptor is composed of a ligand-binding α-chain and the signal
transducer gp130 that contains six tyrosines in its cytoplasmic region, among which
Tyr 759 is required for activation via STAT3 of SOCS3, which is STAT proteins’
competitor for binding the IL-12 receptor and for phosphorylation by Jak-2(Yamamoto
et al. 2003, Nishihara et al. 2007). It is also possible that the 2D6 cell line does not
express the IL-6 receptor on its surface, rendering the cell unresponsive to IL-6
mediated signal for activation. In recent unpublished work in our research group it
was found that these cells do not respond to stimulation with IFN-γ (data not shown),
so perhaps they do not respond to IL-6 either. Verification of the presence of the IL-6
receptor, namely the g130 signal transducer on the surface of 2D6 Th1 cells should
provide more insight into the lack of an observed effect of IL-6 on these cells.

4.2 Conclusion
The assay allowed the observation of a significant inhibition exerted by TGF-β on
2D6 cells. Subtle effects were observed when the cell groups were incubated with
insulin, however the cross-talk between insulin and IL-12 signaling remains unclear. It
is necessary to observe the effects on more proteins downstream the receptor (e.g.
IRS-1) to understand the phenomenon. In addition longer incubation times may allow
the observation of a more significant effect.
Regarding cross-talk between IL-6 and IL-12, It is possible that the 2D6 cell line
does not respond to IL-6 due to a lack of receptor expression. Either using more than
one cell model or a different one, or studying the effect on other molecules
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downstream of inhibitor-binding to cell surface is recommended for future
experiments.
In general the assay designed was able to provide with answers about inhibitiory
effects of the factors studied on IL-12 signaling despite a relatively restricted time frame.
However, more questions need to be answered to fully understand the effect of each
factor.
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APPENDIX A
Sample R/Bioconductor code for analysis of data
#In this experiment, we starved the 2D6 cells for 12 hours without
IL-12,prior to stimulation with insulin.
#The cell line used is the 2D6 cell line, a T helper cell line.

The

cells were
#stained

for

IL-12R$\beta$2,

and

pSTAT4

at

time

0hr,-

12hr,15min,1hr,2hr following the addition of insulin and/or IL-12.
#The concentrations of IL-12, aliquoted in BSA, is 40ng/ml. Cell
density and ratio of 2D6 and B16 changes.
#normally 2D6 at 6 x 10^4 cell$/well$, 2-stand for 2D6 at 1.2 x 10^5
cell$/well$.
library(flowCore)
library(flowViz)
library(flowUtils)
library(geneplotter)
library(colorspace)
library(grid)
library(MASS)
memory.limit(size=2000)
memory.size(max = FALSE)
fclist <- c("./data102610/01-T0-ds-1.fcs",
"./data102610/02-T0-ds-2.fcs",
"./data102610/03-T0-ds-3.fcs",
"./data102610/04-T-12h-ds-1.fcs",
"./data102610/05-T-12h-ds-2.fcs",
"./data102610/06-T-12h-ds-3.fcs",
"./data102610/07-T15m-IL12-Ins-ds-1.fcs",
"./data102610/08-T15m-IL12-Ins-ds-2.fcs",
"./data102610/09-T15m-IL12-Ins-ds-3.fcs",
"./data102610/10-T15m-Ins-ds-1.fcs",
"./data102610/11-T15m-Ins-ds-2.fcs",
"./data102610/12-T15m-Ins-ds-3.fcs",
"./data102610/13-T15m-IL12-ds-1.fcs",
"./data102610/14-T15m-IL12-ds-2.fcs",
"./data102610/15-T15m-IL12-ds-3.fcs",
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"./data102610/16-T15m-nostim-ds-1.fcs",
"./data102610/17-T15m-nostim-ds-2.fcs",
"./data102610/18-T15m-nostim-ds-3.fcs",
"./data102610/19-T1h-IL12-Ins-ds-1.fcs",
"./data102610/20-T1h-IL12-Ins-ds-2.fcs",
"./data102610/21-T1h-IL12-Ins-ds-3.fcs",
"./data102610/22-T1h-Ins-ds-1.fcs",
"./data102610/23-T1h-Ins-ds-2.fcs",
"./data102610/24-T1h-Ins-ds-3.fcs",
"./data102610/25-T1h-IL12-ds-1.fcs",
"./data102610/26-T1h-IL12-ds-2.fcs",
"./data102610/27-T1h-IL12-ds-3.fcs",
"./data102610/28-T1h-nostim-ds-1.fcs",
"./data102610/29-T1h-nostim-ds-2.fcs",
"./data102610/30-T1h-nostim-ds-3.fcs",
"./data102610/31-T2h-IL12-Ins-ds-1.fcs",
"./data102610/32-T2h-IL12-Ins-ds-2.fcs",
"./data102610/33-T2h-IL12-Ins-ds-3.fcs",
"./data102610/34-T2h-Ins-ds-1.fcs",
"./data102610/35-T2h-Ins-ds-2.fcs",
"./data102610/36-T2h-Ins-ds-3.fcs",
"./data102610/37-T2h-IL12-ds-1.fcs",
"./data102610/38-T2h-IL12-ds-2.fcs",
"./data102610/39-T2h-IL12-ds-3.fcs",
"./data102610/40-T2h-nostim-ds-1.fcs",
"./data102610/41-T2h-nostim-ds-2.fcs",
"./data102610/42-T2h-nostim-ds-3.fcs" )
#for compensation matrix only -com
fclistcom <- c("./data102610/T15m-ns-control.fcs",
"./data102610/T15m-ss-IL12RB2.fcs",
"./data102610/T15m-ss-pSTAT4.fcs")
fs <- read.flowSet(fclist, transformation = FALSE)
fscom <- read.flowSet(fclistcom, transformation = FALSE)
Tclist <- c("01-T0-ds-1",
"02-T0-ds-2",
"03-T0-ds-3",
"04-T-12h-ds-1",
"05-T-12h-ds-2",
"06-T-12h-ds-3",
"07-T15m-IL12-Ins-ds-1",
"08-T15m-IL12-Ins-ds-2",
"09-T15m-IL12-Ins-ds-3",
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"10-T15m-Ins-ds-1",
"11-T15m-Ins-ds-2",
"12-T15m-Ins-ds-3",
"13-T15m-IL12-ds-1",
"14-T15m-IL12-ds-2",
"15-T15m-IL12-ds-3",
"16-T15m-nostim-ds-1",
"17-T15m-nostim-ds-2",
"18-T15m-nostim-ds-3",
"19-T1h-IL12-Ins-ds-1",
"20-T1h-IL12-Ins-ds-2",
"21-T1h-IL12-Ins-ds-3",
"22-T1h-Ins-ds-1",
"23-T1h-Ins-ds-2",
"24-T1h-Ins-ds-3",
"25-T1h-IL12-ds-1",
"26-T1h-IL12-ds-2",
"27-T1h-IL12-ds-3",
"28-T1h-nostim-ds-1",
"29-T1h-nostim-ds-2",
"30-T1h-nostim-ds-3",
"31-T2h-IL12-Ins-ds-1",
"32-T2h-IL12-Ins-ds-2",
"33-T2h-IL12-Ins-ds-3",
"34-T2h-Ins-ds-1",
"35-T2h-Ins-ds-2",
"36-T2h-Ins-ds-3",
"37-T2h-IL12-ds-1",
"38-T2h-IL12-ds-2",
"39-T2h-IL12-ds-3",
"40-T2h-nostim-ds-1",
"41-T2h-nostim-ds-2",
"42-T1h-nostim-ds-3")

Tclistcom <- c("T15m-ns-control",
"T15m-ss-IL12RB2",
"T15m-ss-pSTAT4")
rectGate <- rectangleGate(filterId="FSC+",`FSC-A`=c(31000,Inf))
#rectCD45Gate <- rectangleGate(filterId=" PerCP-Cy5-5-A+",`PerCP-Cy55-A`=c(100,Inf))
morphGate <- norm2Filter(filterId = "MorphologyGate", "FSC-A", "SSCA", scale = 2)
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#KMGate <- kmeansFilter(filterId ="kmfilt1", `LD` = c("Low","High"))
rectGate2 <- rectangleGate(filterId="LD2n", `LD2`=c(-Inf,-7000))
RA=-40/180*pi
Tfs <- transform(fs, `LD` = (cos(RA)*`FSC-A` - sin(RA)*`SSC-A`),`LD2`
= (sin(RA)*`FSC-A` + cos(RA)*`SSC-A`))
Tfscom <- transform(fscom, `LD` = (cos(RA)*`FSC-A` - sin(RA)*`SSCA`),`LD2` = (sin(RA)*`FSC-A` + cos(RA)*`SSC-A`))
#compensation
#PosTFS <- Subset(Tfs, morphGate & rectGate2 & rectGate)
#PosTFScom <- Subset(Tfscom, morphGate & rectGate2 & rectGate)

PosTFS <- Subset(Tfs, rectGate)
PosTFS <- Subset(PosTFS, rectGate2)
PosTFS <- Subset(PosTFS, morphGate)
PosTFScom <- Subset(Tfscom, rectGate)
PosTFScom <- Subset(PosTFScom, rectGate2)
PosTFScom <- Subset(PosTFScom, morphGate)
pdf("ld_data102610.pdf")
opar <- par(mfrow=c(2, 2), mar=c(4,4,2,2))
for (i in 1:8) {
# Plot results from rectangular and morphology gate
plot(Tfs[[i]], c("LD", "LD2"),
xlab

=

"LD",

xlim

=

c(0,150000),

ylab

=

"LD2",

ylim

=

c(-

30000,40000),
nrpoints = 1000)
lines(c(0,150000),c(000,000))
}
dev.off()
Total <- as.numeric(fsApply(fs, nrow, use.exprs = TRUE))
MaxTime <- as.numeric(fsApply(fs, each_col, max))[1:length(fs)]
Dens <- Total/MaxTime
Live <- as.numeric(fsApply(PosTFS, nrow, use.exprs = TRUE))
DensLiv <- Live/MaxTime
data1 <- data.frame("Files" = Tclist, "Total Cells" = Total,
"Live

Cells"

=

Live,

"Cell

DensLiv)
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Dens"

=

Dens,

"Live

Dens"

=

data1 <- transform(data1, `Percent` = data1[,3]*100/data1[,2])
tabS1 <- as.matrix(data1)
write.csv(tabS1, file="cellviability 102610.csv")
#jpeg("fscsscvs1.jpg")
pdf("data102610.pdf",width=8.5,height=11)
opar <- par(mfrow=c(2,2), mar=c(4,4,2,2))
Ptxt = Tclist
for (i in 1:42) {
# Plot results from rectangular and morphology gate
plot(fs[[i]], c('FSC-A', 'SSC-A'),
xlab = "FSC", xlim = c(0,262144),
ylab = "SSC", ylim = c(0,262144),
nrpoints = 1000)
title(main=Ptxt[i], outer = FALSE, adj=0, cex.main = 1)
# Calculate 2-dimensional marginalized densities
lims1 <- c(0,262144,0,262144)
N.density <- kde2d(exprs(PosTFS[[i]][,2]),exprs(PosTFS[[i]][,3]),
n=361, lims=lims1)
# Superimpose 100% contour lines on scatter plots
contour(N.density,

levels=c(1e-10),

add=TRUE,

col="red",

labels="95", lwd=3)
}
nspill.mat <- description(PosTFS[[1]])$SPILL
nspill.mat
# these need to be specified in a particular order
# 1. unstained control
# 2. single stain for first column after SSC-A
# 3. single stain for second column after SSC-A
# etc
#Use a kmeansFilter to select high expression groups
# use data set '04' for compensation calculation because the first 4
is signle stain control
#kmfilt1

<-

kmeansFilter(filterId="kmfilt1",

"FITC-A"

=

c("Low",

"High"))
#FITC04.high

<-

fsApply(PosTFS04[2],

kmfilt1)$High)
#FITC.high <- PosTFScom[2]
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function(x)

split(x,

#kmfilt2

<-

kmeansFilter(filterId="kmfilt2",

"PE-A"

=

c("Low",

"High"))
#PE04.high

<-

fsApply(PosTFS04[3],

function(x)

split(x,

kmfilt2)$High)
#PE.high <-

PosTFScom[3]

#kmfilt3 <- kmeansFilter(filterId="kmfilt3", "Alexa 647-A" = c("Low",
"High"))
#ALEXA04.high

<-

fsApply(PosTFS04[4],

function(x)

split(x,

kmfilt3)$High)
#Combine resulting flowFrames into a flowSet
FiltFS = PosTFScom[c(1:3)]
#FiltFS

=

flowSet(PosTFScom[[1]],FITC.high[[1]],

PE.high[[1]],

PerCP.high[[1]], ALEXA.high[[1]])

#Calculate the background intensity for each parameter
#CMed = as.matrix(fsApply(FiltFS, each_col, median)[,-c(1:3)])
CMed = as.matrix(fsApply(FiltFS, each_col, median)[,-c(1:3,6,7)])
#CMed04 = as.matrix(fsApply(FiltFS04, each_col, median)[,-c(1:4)])

#Sweep out medians determined from unstained control from single
stained
#controls
#bFiltFS <- transform(FiltFS, `FITC-A`=`FITC-A` - min(CMed[,1]), `PEA`=`PE-A`-min(CMed[,2]),`PerCP-Cy5-5-A`=`PerCP-Cy5-5-A`min(CMed[,3]),
#

`Alexa 647-A`=`Alexa 647-A`-min(CMed[,4]))

bFiltFS <- transform(FiltFS, `FITC-A`=`FITC-A` - min(CMed[,1]),
`Alexa 647-A`=`Alexa 647-A`-min(CMed[,2]))

#Capture medians from single-stained flowFrames
#FObs04 = as.matrix(fsApply(bFiltFS04[c(2:4)], each_col, median)[,c(1:4,6:7)])
FObs

=

as.matrix(fsApply(bFiltFS[c(2:3)],

each_col,

median)[,-

c(1:3,6:7)])
#For the FObs matrix, when the one for the particular experiment does
not work (as in this case)
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#FObs <- read.csv(file="FObs.csv",header=TRUE,sep=",");
FObs
#Estimate compensation spillover matrix
fij = solve(FObs) %*% diag(diag(FObs))
#fij04 = solve(FObs04) %*% diag(diag(FObs04))
#Display new spillover matrix
#When there is spillover of IL12 into pSTAT4 channel
#fij <- read.csv(file="nspill060810.csv",header=TRUE,sep=",");
fij
# Apply calculated compensation matrix to compensation
bPos2D6com <- transform(PosTFScom, `FITC-A`=`FITC-A` - min(CMed[,1]),
`Alexa 647-A`=`Alexa 647-A`-min(CMed[,2]))
cPos2D6com <- transform(bPos2D6com,
`cFITCA`=fij[1,1]*`FITC-A` + fij[2,1]*`Alexa 647-A`,
`cAlexa647A`=fij[1,2]*`FITC-A` + fij[2,2]*`Alexa 647-A`)
#apply to whole flow set
bPos2D6 <- transform(PosTFS, `FITC-A`=`FITC-A` - min(CMed[,1]),
`Alexa 647-A`=`Alexa 647-A`-min(CMed[,2]))
cPos2D6 <- transform(bPos2D6,
`cFITCA`=fij[1,1]*`FITC-A` + fij[2,1]*`Alexa 647-A`,
`cAlexa647A`=fij[1,2]*`FITC-A`+ fij[2,2]*`Alexa 647-A`)

linlogTransform = function(transformationId, median = 0, dist = 1,
...)
{
tr <- new("transform", .Data = function(x){
idx = which(x <= median + dist)
idx2 = which(x > median + dist)
if (length(idx2) > 0) {
x[idx2] = log10(x[idx2] - median) - log10(dist/exp(1))
}
if (length(idx) > 0) {
x[idx] = 1/dist * log10(exp(1))*(x[idx] - median)
}
x
})
tr@transformationId = transformationId
tr
}
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lnlgT

<-

linlogTransform(transformationId="splitscale",

median=0,

dist=100)
#Calculate X-labels for graphs
lnlgTGraphs

<-

linlogTransform(transformationId="splitscale",

median=0, dist=100)
Xloc <- lnlgTGraphs(c(-200, -150, -100, -50, 0, 50, 100, 150, 200,
250, 400, 550, 700, 850, 1000,
2500, 4000, 5500, 7000, 8500, 10000,
25000, 40000, 55000, 70000, 85000, 100000))
Xlab <- c(-200,' ',-100,' ',0,' ',100, ' ', ' ', ' ', ' ', ' ', ' ',
' ',
expression(10^3), ' ', ' ', ' ', ' ', ' ', expression(10^4),
' ', ' ', ' ', ' ', ' ', expression(10^5))
cPos2D6com <- transform(cPos2D6com, `IL12RB2`=lnlgT(`cFITCA`),
`pSTAT4`=lnlgT(`cAlexa647A`))
cPos2D6 <- transform(cPos2D6, `IL12RB2`=lnlgT(`cFITCA`),
`pSTAT4`=lnlgT(`cAlexa647A`))

#get 'B1/B2', 'S4/B2' and 'S4/B1'
cPos2D6com <- transform(cPos2D6com, `S4B2`=`cAlexa647A`/`cFITCA`)
cPos2D6 <- transform(cPos2D6, `S4B2`=`cAlexa647A`/`cFITCA`)
Plim = c(-0.5, 2.25)
#Set up themes for all subsequent lattice figures
trellis.par.set(theme = col.whitebg())
lw <- list(ylab.axis.padding = list(x = 0.5),
left.padding = list(x = 0.1, units = "inches"),
right.padding = list(x = 0, units = "inches"),
panel = list(x = 1.5, units = "inches"))
lh <- list(bottom.padding = list(x = 0, units = "inches"),
top.padding <- list(x = 0, units = "inches"),
panel = list(x = 1.5, units = "inches"))
lattice.options(layout.widths = lw, layout.heights = lh)
cPos2D6com2

<-

Subset(cPos2D6com,

rectangleGate(filterId="fpSTAT4",`pSTAT4`=c(-3,Inf)))
fsApply(cPos2D6com2, nrow)
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# Plot results from spillover compensation
#tp1

<-

xyplot(`IL12RB2`~`IL12RB1`|name,

cPos2D6com2[c(1:5)],

nrpoints = 1000,
#

labels = FALSE, layout=c(1, 5), aspect=1,

#

xlab = "IL12RB1", xlim = Plim, ylab = "IL12RB2", ylim =

Plim,
#

scales = list(x = list(at=Xloc, labels=Xlab),

#

y = list(at=Xloc, labels=Xlab, rot=0)),

#

strip = strip.custom(factor.levels = Tclistcom[c(1:5)]),

#

panel = function(x, frames, channel.x, channel.y, ...){

#

panel.xyplot.flowset(x, frames, channel.x, channel.y,

...)
#

llines(c(-0.5,2.5),c(0,0))

#

llines(c(0,0),c(-0.5,2.5))

#
#tp2

})
<-

xyplot(`pSTAT4`~`IL12RB1`|name,

cPos2D6com2[c(1:5)],

nrpoints = 1000,
#

labels = FALSE, layout=c(1, 5), aspect = 1,

#

xlab = "IL12RB1", xlim = Plim, ylab = "pSTAT4", ylim = Plim,

#

scales = list(x = list(at=Xloc, labels=Xlab),

#

y = list(at=Xloc, labels=Xlab, rot=0)),

#

strip = strip.custom(factor.levels = Tclistcom[c(1:5)]),

#

panel = function(x, frames, channel.x, channel.y, ...){

#

panel.xyplot.flowset(x, frames, channel.x, channel.y,

...)
#

llines(c(-0.5,2.5),c(0,0))

#

llines(c(0,0),c(-0.5,2.5))

#
tp3 <-

})
xyplot(`IL12RB2`~`pSTAT4`|name, cPos2D6com2[c(1:3)], nrpoints

= 1000,
labels = FALSE, layout=c(1, 3), aspect = 1,
xlab = "pSTAT4", xlim = Plim, ylab = "IL12RB2", ylim = Plim,
scales = list(x = list(at=Xloc, labels=Xlab),
y = list(at=Xloc, labels=Xlab, rot=0)),
#

strip = strip.custom(factor.levels = Tclistcom[c(1:3)]),
panel = function(x, frames, channel.x, channel.y, ...){
panel.xyplot.flowset(x,

frames,

...)
llines(c(-0.5,2.5),c(0,0))
llines(c(0,0),c(-0.5,2.5))
})
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channel.x,

channel.y,

#jpeg(filename = "2D6-SS.jpg", width = 1024, height = 1024)
#pdf("2D6-SS.pdf")
# plot(tp1, position = c(0, 0, 0.33, 1), more=TRUE)
# plot(tp2, position = c(0.33, 0, 0.66, 1), more=TRUE)
plot(tp3, more=FALSE)
#source("filename")
#dev.off() # End plot

#####################################################################
############################################################

#define positive limits
# IL12RB2 - from Unstained control experiment
RB21 <- density(exprs(cPos2D6com[[1]])[,10])
CumV <- 0
limRB21 <- 0
while (CumV < 0.95){
limRB21 <- limRB21 + 1
CumV <- sum(RB21$y[1:limRB21])/sum(RB21$y)
}
# IL12RB2 - from pSTAT4 single-stained control experiment
RB23 <- density(exprs(cPos2D6com[[3]])[,10])
CumV <- 0
limRB23 <- 0
while (CumV < 0.95){
limRB23 <- limRB23 + 1
CumV <-sum(RB23$y[1:limRB23])/sum(RB23$y)
}
ValRB2 <- max(c(RB21$x[limRB21],RB23$x[limRB23]))
#define positive limits
# pSTAT4 - from unstimulated control experiment1
S41 <- density(exprs(cPos2D6com[[1]])[,11])
CumV <- 0
limS41 <- 0
while (CumV < 0.95){
limS41 <- limS41 + 1
CumV <- sum(S41$y[1:limS41])/sum(S41$y)
}
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# pSTAT4 - from unstimulated control experiment2
S42 <- density(exprs(cPos2D6[[2]])[,11])
CumV <- 0
limS42 <- 0
while (CumV < 0.95){
limS42 <- limS42 + 1
CumV <- sum(S42$y[1:limS42])/sum(S42$y)
}
ValSTAT4 <- max(c(S41$x[limS41],S42$x[limS42]))
tp1

<-

xyplot(`pSTAT4`~`IL12RB2`|name,

cPos2D6com[c(1,2,3)],

nrpoints = 1000,
labels = FALSE, layout=c(1, 3), aspect=1,
xlab = "IL12RB2", xlim = Plim, ylab = "pSTAT4", ylim = Plim,
scales = list(x = list(at=Xloc, labels=Xlab),
y = list(at=Xloc, labels=Xlab, rot=0)),
#strip = strip.custom(factor.levels = Tclistcom[c(1,2,3)]),
panel = function(x, frames, channel.x, channel.y, ...){
panel.xyplot.flowset(x,

frames,

channel.x,

channel.y,

...)
llines(c(0,0),c(-1,2.75))
llines(c(-1,2.75), c(0,0),lty=2)
})

plot(tp1, position = c(0, 0, 1, 1), more=FALSE)
tr1

<-

xyplot(`pSTAT4`~`IL12RB2`|factor(name,levels=unique(name)),

cPos2D6[c(1:12)], nrpoints = 1000,
labels = FALSE, layout=c(3,4), aspect=1,
xlab = "IL12RB2", xlim = Plim, ylab = "pSTAT4", ylim = Plim,
scales = list(x = list(at=Xloc, labels=Xlab),
y = list(at=Xloc, labels=Xlab, rot=0)),
#strip

=

strip.custom(factor.levels

=

Tclist[c(1,4,7,10,13,16)]),
panel = function(x, frames, channel.x, channel.y, ...){
panel.xyplot.flowset(x,

frames,

channel.x,

channel.y,

...)
llines(c(ValRB2,ValRB2),c(-1,2.75))
llines(c(-1,2.75), c(ValSTAT4,ValSTAT4),lty=2)
})
tr2

<-

xyplot(`pSTAT4`~`IL12RB2`|factor(name,levels=unique(name)),
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cPos2D6[c(13:24)], nrpoints = 1000,
labels = FALSE, layout=c(3,4), aspect=1,
xlab = "IL12RB2", xlim = Plim, ylab = "pSTAT4", ylim = Plim,
scales = list(x = list(at=Xloc, labels=Xlab),
y = list(at=Xloc, labels=Xlab, rot=0)),
#strip

=

strip.custom(factor.levels

=

Tclist[c(2,5,8,11,14,17)]),
panel = function(x, frames, channel.x, channel.y, ...){
panel.xyplot.flowset(x,

frames,

channel.x,

channel.y,

...)
llines(c(ValRB2,ValRB2),c(-1,2.75))
llines(c(-1,2.75), c(ValSTAT4,ValSTAT4),lty=2)
})
tr3

<-

xyplot(`pSTAT4`~`IL12RB2`|factor(name,levels=unique(name)),

cPos2D6[c(25:42)], nrpoints = 1000,
labels = FALSE, layout=c(3,4), aspect=1,
xlab = "IL12RB2", xlim = Plim, ylab = "pSTAT4", ylim = Plim,
scales = list(x = list(at=Xloc, labels=Xlab),
y = list(at=Xloc, labels=Xlab, rot=0)),
#strip

=

strip.custom(factor.levels

=

Tclist[c(3,6,9,12,15)]),
panel = function(x, frames, channel.x, channel.y, ...){
panel.xyplot.flowset(x,

frames,

channel.x,

channel.y,

...)
llines(c(ValRB2,ValRB2),c(-1,2.75))
llines(c(-1,2.75), c(ValSTAT4,ValSTAT4),lty=2)
})

plot(tr1)#position = c(0, 0, 0.33, 1), more=TRUE)
plot(tr2)# position = c(0.34, 0, 0.66, 1), more=TRUE)
plot(tr3)# position = c(0.67, 0, 1, 1), more=FALSE)
# For histogram
yrng<-c(0,2.5)
xrng<-c(-0.5,2.5)
opar<-par(mfcol=c(2,2),mar=c(4,4,2,2))
Pidx=c(1,4,7,10)
Plty=c(1,2,3,4)
Pcols<-c("red","darkgreen","blue","black")
plot(density(exprs(cPos2D6[[Pidx[1]]])[,11],na.rm=TRUE,kernel="rect")
,
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col=Pcols[1],xlab="pSTAT4",xlim=xrng,ylab="Density",
main="",ylim=yrng,xaxt="n",lwd=2,lty=1)
title(main="A",outer=FALSE,adj=0,cex.main=1)
axis(1,Xloc,labels=Xlab)
for(i in 2:length(Pidx)){
lines(density(exprs(cPos2D6[[Pidx[i]]])[,11],na.rm=TRUE,
kernel="rect"),col=Pcols[i],lwd=2,lty=Plty[i])
#Plot Beta 2
pdf("B2-histograms102610.pdf", width = 6.25, height = 6.25)
plot(density(exprs(cPos2D6com[[19]])[,10], na.rm = TRUE), type = "n",
col=1, xlab = expression(paste("IL-12R",beta,"2 (MFI)")), xlim =
c(-0.5,2.0), xaxt = "n",
ylab ="Normalized Density", ylim = c(0,1),main = "")
BG = density(exprs(cPos2D6com[[1]])[,10], na.rm=TRUE, from = -0.5, to
= 2)
polygon(BG$x, BG$y/max(BG$y), col=gray(0.7))
#lines(BG$x, BG$y/max(BG$y), col=gray(0.7), lwd=2, lty=1)
L1 <- density(exprs(cPos2D6com[[2]])[,10], na.rm=TRUE, from = -0.5,
to = 2)
lines(L1$x, L1$y/max(L1$y), col="black", lwd=2, lty=1)
L2 <- density(exprs(cPos2D6com[[3]])[,10], na.rm=TRUE, from = -0.5,
to = 2)
lines(L2$x, L2$y/max(L2$y), col="red", lwd=2, lty=1)
axis(1, Xloc, labels=Xlab)
dev.off()
#Plot pSTAT4
pdf("pSTAT4-histograms102610.pdf", width = 6.25, height = 6.25)
plot(density(exprs(cPos2D6com[[1]])[,11], na.rm = TRUE), type = "n",
col=1, xlab = expression(paste("pSTAT"," 4 (MFI)")), xlim = c(0.5,2.0), xaxt = "n",
ylab ="Normalized Density", ylim = c(0,1),main = "")
BG = density(exprs(cPos2D6com[[1]])[,11], na.rm=TRUE, from = -0.5, to
= 2)
polygon(BG$x, BG$y/max(BG$y), col=gray(0.7))
#lines(BG$x, BG$y/max(BG$y), col=gray(0.7), lwd=2, lty=1)
L1 <- density(exprs(cPos2D6com[[2]])[,11], na.rm=TRUE, from = -0.5,
to = 2)
lines(L1$x, L1$y/max(L1$y), col="black", lwd=2, lty=1)
L2 <- density(exprs(cPos2D6com[[3]])[,11], na.rm=TRUE, from = -0.5,
to = 2)
lines(L2$x, L2$y/max(L2$y), col="red", lwd=2, lty=1)
axis(1, Xloc, labels=Xlab)
dev.off()
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}

#use the B2 possitive gate defined before
#rectB2Gate <- rectangleGate(filterId="cFITC+",`cFITC`=c(300,500))
#RB2PGate

<-

rectangleGate(filterId="IL12RB2+",`IL12RB2`=c(ValRB2,Inf))
#RB2P = Subset(cPos2D6, RB2PGate)
#RB2P04 = Subset(cPos2D604, rectB2Gate)
#RB2P524 = Subset(cPos2D6524, rectB2Gate)
Total = vector('list',42)
mRB2 = vector('list',42)
mSTAT4 = vector('list',42)
mS4B2 = vector('list',42)
# use the compensation numbers here show statistic [10],[11],[12]and
[18],[19],[20]
for (i

in 1:42) {

Total[[i]] <- nrow(cPos2D6[[i]])
mRB2[[i]] <- fsApply(cPos2D6[i], each_col, median)[,10]
mSTAT4[[i]] <- fsApply(cPos2D6[i], each_col, median)[,11]
mS4B2[[i]] <- fsApply(cPos2D6[i], each_col, median)[,12]
}
#summary(cPos2D6com2[[4]])#to view matrix with values
data31 <- data.frame("Experiment" = Tclist[c(1:42)],
"Total Cells" = as.numeric(Total),
"MFI IL12RB2" = as.numeric(mRB2),
"MFI pSTAT4" = as.numeric(mSTAT4),
"MFI S4B2" = as.numeric(mS4B2))
tab31<- as.matrix(data31)
tab31
dev.off() # End plot
summary (cPos2D6)
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APPENDIX B
Representative no stain and single stain control plots

Figure 1. Single stain controls for pSTAT4 and IL-12Rβ2 used for compensation
by representing each one a positive signal in its own channel only. Top panels
are no stain controls, middle left and bottom right are single stain controls for
IL-12Rβ2, and middle right and bottom left are single stain controls for pSTAT4.

66

APPENDIX C
Statistical analysis of treatment groups

1. Effect of TGF-β on pSTAT4
1.1 Effect of TGF-β after 15 minutes
Two-way ANOVA: pSTAT4 versus TGF-beta; IL-12
Source

DF

SS

MS

F

P

TGF-beta

1

42,075

42,075

6,77

0,031

IL-12

1

325,833

325,833

52,46

0,000

Interaction

1

25,667

25,667

4,13

0,077

Error

8

49,688

6,211

Total

11

443,263

S = 2,492

R-Sq = 88,79%

R-Sq(adj) = 84,59%

1.2 Effect of TGF-β after 1 hour
Two-way ANOVA: pSTAT4 versus TGF-beta; IL-12
Source

DF

SS

MS

F

P

TGF-beta

1

257,75

257,752

1,46

0,262

IL-12

1

486,60

486,604

2,75

0,136

Interaction

1

51,32

51,315

0,29

0,605

Error

8

1415,78

176,973

Total

11

2211,46

S = 13,30

R-Sq = 35,98%

R-Sq(adj) = 11,97%

1.3 Effect of TGF-β after 2 hours
Two-way ANOVA: pSTAT4 versus TGF-beta; IL-12
Source

DF

SS

MS

F

P

TGF-beta

1

1842,89

1842,89

103,08

0,000

IL-12

1

4681,15

4681,15

261,84

0,000
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Interaction

1

925,59

925,59

Error

8

143,02

17,88

Total

11

7592,64

S = 4,228

R-Sq = 98,12%

51,77

0,000

R-Sq(adj) = 97,41%

2. Effect of TGF-β on cell viability
2.1 Effect of TGF-β after 15 minutes
Two-way ANOVA: Live cell percent versus TGF-beta; IL-12
Source

DF

SS

MS

F

P

TGF-beta

1

0,074

0,0736

0,01

0,939

IL-12

1

19,051

19,0512

1,63

0,237

Interaction

1

16,709

16,7088

1,43

0,265

Error

8

93,233

11,6541

Total

11

129,066

S = 3,414

R-Sq = 27,76%

R-Sq(adj) = 0,68%

2.2 Effect of TGF-β after 1 hour
Two-way ANOVA: Live cell percent versus TGF-beta; IL-12
Source

DF

SS

MS

F

P

TGF-beta

1

251,534

251,534

9,85

0,014

IL-12

1

2,595

2,595

0,10

0,758

Interaction

1

77,216

77,216

3,02

0,120

Error

8

204,232

25,529

Total

11

535,576

S = 5,053

R-Sq = 61,87%

R-Sq(adj) = 47,57%

2.3 Effect of TGF-β after 2 hours
Two-way ANOVA: Live cell percent versus TGF-beta; IL-12
Source

DF

SS

MS

F

P

TGF-beta

1

256,364

256,364

22,41

0,001

IL-12

1

124,775

124,775

10,91

0,011
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Interaction

1

164,317

164,317

Error

8

91,516

11,439

Total

11

636,972

S = 3,382

R-Sq = 85,63%

14,36

0,005

R-Sq(adj) = 80,24%

3. Effect of time and treatment with insulin
3.1 Effect of Insulin after 15 minutes
Two-way ANOVA: pSTAT4 versus Insulin; IL-12
Source

DF

SS

MS

F

P

Insulin

1

2,253

2,253

0,17

0,694

IL-12

1

126,750

126,750

9,38

0,016

Interaction

1

36,053

36,053

2,67

0,141

Error

8

108,160

13,520

Total

11

273,217

S = 3,677

R-Sq = 60,41%

R-Sq(adj) = 45,57%

3.2 Effect of Insulin after 1 hour
Two-way ANOVA: pSTAT4 versus Insulin; IL-12
Source

DF

SS

MS

F

P

Insulin

1

29,610

29,610

6,62

0,033

IL-12

1

498,585

498,585

111,50

0,000

Interaction

1

65,100

65,100

14,56

0,005

Error

8

35,772

4,471

Total

11

629,067

S = 2,115

R-Sq = 94,31%

R-Sq(adj) = 92,18%

2.3 Effect of Insulin after 2 hours
Two-way ANOVA: pSTAT4 versus Insulin; IL-12
Source
Insulin

DF

SS

MS

F

P

1

1,73

1,73

0,54

0,484

69

IL-12

1

1128,11

1128,11

352,10

0,000

Interaction

1

65,10

65,10

20,32

0,002

Error

8

25,63

3,20

Total

11

1220,57

S = 1,790

R-Sq = 97,90%

R-Sq(adj) = 97,11%

4. Effect of insulin on cell viability
4.1 Effect of Insulin after 15 minutes
Two-way ANOVA: Live cell percent versus Insulin; IL-12
Source

DF

SS

MS

F

P

Insulin

1

0,0001

0,00013

0,00

0,995

IL-12

1

3,8307

3,83070

1,17

0,311

Interaction

1

2,8421

2,84213

0,87

0,379

Error

8

26,1760

3,27200

Total

11

32,8490

S = 1,809

R-Sq = 20,31%

R-Sq(adj) = 0,00%

4.2 Effect of Insulin after 1 hour
Two-way ANOVA: Live cell percent versus Insulin; IL-12
Source

DF

SS

MS

F

P

Insulin

1

20,4363

20,4363

5,78

0,043

IL-12

1

6,9921

6,9921

1,98

0,197

Interaction

1

1,0208

1,0208

0,29

0,606

Error

8

28,2636

3,5329

Total

11

56,7129

S = 1,880

R-Sq = 50,16%

R-Sq(adj) = 31,48%

4.3 Effect of Insulin after 2 hours
Two-way ANOVA: Live cell percent versus Insulin; IL-12
Source

DF

SS

MS

F
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P

Insulin

1

6,571

6,5712

0,89

0,374

IL-12

1

24,596

24,5960

3,31

0,106

Interaction

1

40,333

40,3333

5,43

0,048

Error

8

59,386

7,4233

Total

11

130,887

S = 2,725

R-Sq = 54,63%

R-Sq(adj) = 37,61

5. Effect of IL-6 on pSTAT4
5.1 Effect of IL-6 after 15 minutes
Two-way ANOVA: pSTAT4 versus IL-6; IL-12
Source

DF

SS

MS

F

P

IL-6

1

266,492

266,492

4,18

0,075

IL-12

1

0,317

0,317

0,00

0,946

Interaction

1

59,185

59,185

0,93

0,364

Error

8

510,098

63,762

Total

11

836,092

S = 7,985

R-Sq = 38,99%

R-Sq(adj) = 16,11%

5.2 Effect of IL-6 after 1 hour
Two-way ANOVA: pSTAT4 versus IL-6; IL-12
Source

DF

SS

MS

F

P

IL-6

1

2,25

2,253

0,07

0,794

IL-12

1

225,33

225,333

7,27

0,027

Interaction

1

813,45

813,453

26,25

0,001

Error

8

247,87

30,983

Total

11

1288,91

S = 5,566

R-Sq = 80,77%

R-Sq(adj) = 73,56%

5.3 Effect of IL-6 after 2 hours
Two-way ANOVA: pSTAT4 versus IL-6; IL-12
Source

DF

SS

MS

F
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P

IL-6

1

25,667

25,667

2,31

0,167

IL-12

1

71,297

71,297

6,43

0,035

Interaction

1

198,047

198,047

17,86

0,003

Error

8

88,725

11,091

Total

11

383,736

S = 3,330

R-Sq = 76,88%

R-Sq(adj) = 68,21%

6. Effect of IL-6 on cell viability
6.1 Effect of IL-6 after 15 minutes
Two-way ANOVA: Live cell percent versus IL-6; IL-12
Source

DF

SS

MS

F

P

IL-6

1

1,279

1,2793

0,07

0,798

IL-12

1

0,001

0,0012

0,00

0,994

Interaction

1

10,143

10,1427

0,56

0,477

Error

8

145,589

18,1987

Total

11

157,012

S = 4,266

R-Sq = 7,28%

R-Sq(adj) = 0,00%

6.2 Effect of IL-6 after 1 hour
Two-way ANOVA: Live cell percent versus IL-6; IL-12
Source

DF

SS

MS

F

P

IL-6

1

34,525

34,5252

3,66

0,092

IL-12

1

32,019

32,0193

3,39

0,103

Interaction

1

18,893

18,8925

2,00

0,195

Error

8

75,493

9,4366

Total

11

160,930

S = 3,072

R-Sq = 53,09%

R-Sq(adj) = 35,50%

6.3 Effect of IL-6 after 2 hours
Two-way ANOVA: Live cell percent versus IL-6; IL-12
Source

DF

SS

MS

F

P

IL-6

1

38,815

38,8149

1,86

0,210

IL-12

1

14,881

14,8809

0,71

0,423
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Interaction

1

59,972

59,9718

Error

8

167,328

20,9160

Total

11

280,996

S = 4,573

R-Sq = 40,45%

2,87

0,129

R-Sq(adj) = 18,12%
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APPENDIX D
Protocol for Western Blot
Gel Electrophoresis
1. Place larger glass sheet on bottom (back) and shorter on top (front) and align
using black rubber strips (spacers) on sides.
2. Place glasses vertically on holder, press edges to align.
3. Tighten screws up to first resistance (when too tight, it can leak)
4. Snap onto base and add water to check for leaks.
5. Prepare resolving gel using recipe for 5ml (for 1 gel) or 10 ml (for 2 gels) and 12%
acrilamide.
6. Pour resolving gel up to hinges on sides, and add a bit of water on top to take care
of bubbles (up to top).
7. Let polymerize for 40 minutes.
8. Pour off water from the top of glasses.
9. Prepare 1 or 2 ml of stacking gel as indicated on recipe and pour it on top of
resolving gel.
10. Put comb in between glasses right after pouring gel.
11. After 30 minutes, remove comb upright and wash wells with 1x running buffer.
12. Snap glass holder on unit and pour 1x buffer in inner chamber first, and then fill
up the rest of the chamber.
13. Add SDS 4x buffer to protein samples for a complete volume of 40 μl, and boil
samples for 3 minutes.
14. Pour samples, controls and ladder into the wells making sure it settles on the
bottom.
15. Close chamber and connect to voltage source.
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16. Run at 75V, 350 mA (6h) for 2 hours.

Transfer
1. Cut four 6 x 9 com pieces of blot paper and one 6 x 9 cm piece of membrane for
the transfer.
2. Put cassette sandwich with black part down, then put foam piece on black lid and
pour 1x Transfer Buffer, then put 2 transfer blot papers, then gel as mirror image on
paper, then membrane on top with protein side marked, and repeat sequence in
reverse order (Note: keep moist with 1x Transfer buffer at all times).
3. Place cassette sandwich on unit, black side facing black walls of chamber, and
white edge of cassette up.
4. Place in bigger chamber, black wall in, with ice packet, and fill with buffer almost to
top.
5. Transfer at 42V for 1. 5 hours.
Blotting
1. After transfer is finished take membrane out of chamber and place in a WB box to
block for 1 hr with 10 ml of Odyssey Blocking Buffer and gentle shaking
2. Put membrane in primary antibody solution (10 ml Blocking Buffer + 0.2% Tween
20 + Phospho-Stat3 (Tyr705)-Cell Signaling Technology Inc.) and incubate overnight
at 4°C and gentle shaking.
3. Wash 4x with 10 ml of PBST (PBS + 0.1% Tween 20) for minutes.
4. Put membrane in secondary antibody solution (10 ml Blocking Buffer + 0.2%
Tween 20 + 0.01% SDS + secondary antibody (1:15,000)) and incubate for 1 hour at
room temperature and gentle shaking (Note: Protect from light from this point on).
5. Pour off solution and wash 4x with 10 ml of PBST.
6. Rinse membrane with 1x PBS to remove residual Tween 20.
7. Scan membrane in Li-Cor Infrared Odyssey Scanner.
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